BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35311997)

  • 21. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
    Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
    Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
    Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
    Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
    Qi W; Zhang W; Edwards H; Chu R; Madlambayan GJ; Taub JW; Wang Z; Wang Y; Li C; Lin H; Ge Y
    Cancer Biol Ther; 2015; 16(12):1784-93. PubMed ID: 26529495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
    Alcitepe İ; Salcin H; Karatekin İ; Kaymaz BT
    Med Oncol; 2022 Oct; 39(12):257. PubMed ID: 36224430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
    Maiso P; Colado E; Ocio EM; Garayoa M; Martín J; Atadja P; Pandiella A; San-Miguel JF
    Leukemia; 2009 Dec; 23(12):2265-74. PubMed ID: 19812608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
    Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
    PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
    Blagitko-Dorfs N; Schlosser P; Greve G; Pfeifer D; Meier R; Baude A; Brocks D; Plass C; Lübbert M
    Leukemia; 2019 Apr; 33(4):945-956. PubMed ID: 30470836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
    Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
    Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDAC Inhibitors in Acute Myeloid Leukemia.
    San José-Enériz E; Gimenez-Camino N; Agirre X; Prosper F
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31739588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines.
    Bollmann LM; Skerhut AJ; Asfaha Y; Horstick N; Hanenberg H; Hamacher A; Kurz T; Kassack MU
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
    Hamam HJ; Palaniyar N
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
    Sears TK; Horbinski CM; Woolard KD
    J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.
    Fiskus W; Sharma S; Saha S; Shah B; Devaraj SG; Sun B; Horrigan S; Leveque C; Zu Y; Iyer S; Bhalla KN
    Leukemia; 2015 Jun; 29(6):1267-78. PubMed ID: 25482131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
    Imai Y; Maru Y; Tanaka J
    Cancer Sci; 2016 Nov; 107(11):1543-1549. PubMed ID: 27554046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.
    Forthun RB; Sengupta T; Skjeldam HK; Lindvall JM; McCormack E; Gjertsen BT; Nilsen H
    PLoS One; 2012; 7(11):e48992. PubMed ID: 23155442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways.
    Jia X; Zheng Y; Guo Y; Chen K
    Mol Genet Genomic Med; 2019 May; 7(5):e613. PubMed ID: 30891950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models.
    Schmitz RL; Weissbach J; Kleilein J; Bell J; Hüttelmaier S; Viol F; Clauditz T; Grabowski P; Laumen H; Rosendahl J; Michl P; Schrader J; Krug S
    Cells; 2021 Jun; 10(6):. PubMed ID: 34204116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.